IDEXX Laboratories, Inc. $IDXX Shares Sold by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,149 shares of the company’s stock after selling 976 shares during the period. IDEXX Laboratories comprises approximately 0.8% of EFG Asset Management North America Corp.’s holdings, making the stock its 27th largest holding. EFG Asset Management North America Corp.’s holdings in IDEXX Laboratories were worth $6,483,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in IDXX. Bank of New York Mellon Corp raised its holdings in shares of IDEXX Laboratories by 156.2% during the second quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after purchasing an additional 884,808 shares during the period. Generation Investment Management LLP bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $304,277,000. Norges Bank acquired a new stake in IDEXX Laboratories during the second quarter worth about $221,955,000. Schroder Investment Management Group lifted its holdings in IDEXX Laboratories by 295.1% in the second quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock worth $169,368,000 after acquiring an additional 235,863 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. lifted its holdings in IDEXX Laboratories by 50.3% in the second quarter. Montrusco Bolton Investments Inc. now owns 429,409 shares of the company’s stock worth $224,153,000 after acquiring an additional 143,641 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Trading Up 0.6%

NASDAQ:IDXX opened at $697.82 on Tuesday. The stock has a market cap of $55.72 billion, a price-to-earnings ratio of 55.34, a PEG ratio of 3.71 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The business has a fifty day moving average of $706.41 and a 200-day moving average of $657.44.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The company’s revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research reports. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a research report on Monday, November 3rd. UBS Group upped their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. BTIG Research increased their target price on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a report on Monday, November 3rd. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 17th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $763.50.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.